A federal appeals court ruled Friday.
‘ The White House released a declaration praising the decision, as do the National Institutes of Health . This content was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family members Foundation. Kaiser Health News, an unbiased news service editorially, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research company unaffiliated with Kaiser Permanente.. Appeals court restores government financing of stem cell research THE BRAND NEW York Times: Courtroom Lets U.S. Resume Paying For Embryo Study Government funding of human embryonic stem cell analysis can continue, a federal appeals court ruled Friday.announced today that pacritinib provides been granted Fast Track designation by the U.S. Food and Medication Administration for the treatment of intermediate and high risk myelofibrosis, including however, not limited to individuals with disease related thrombocytopenia, patients suffering from treatment emergent thrombocytopenia on various other JAK2 therapy or individuals who are intolerant to or whose symptoms are sub-optimally managed on various other JAK2 therapy. Pacritinib is an oral tyrosine kinase inhibitor with dual activity against FLT3 and JAK2. The drug candidate is currently being evaluated in two Phase 3 clinical trials, referred to as the PERSIST plan, for sufferers with myelofibrosis. We are very pleased that the pacritinib development program in myelofibrosis has been granted Fast Track designation, and we look forward to continuing to utilize the FDA upon this important drug applicant closely, stated James A.